US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Resolutions of the Constitutive Meeting of the Board of Directors of Nanoform Finland Plc

Company release Nanoform Finland Plc April 15, 2025 14.10 Finnish time / 13.10 Swedish time Resolutions of the Constitutive Meeting of the Board of Directors of Nanoform Finland Plc Nanoform Finland Plc’s (the “Company” or “Nanoform“) Board of Directors held its constitutive meeting on April 15, 2025. The meeting elected the following persons to the Audit and Compensation Committee of the Board of Directors of the Company: Miguel Calado (chairperson) and Jeanne Thoma (ordinary member). Both members have been members of the audit and compensation committee for prior terms,

Resolutions of Nanoform Finland Plc's Annual General Meeting on April 15, 2025

Company release Nanoform Finland Plc April 15, 2025 14.00 Finnish time / 13.00 Swedish time Resolutions of Nanoform Finland Plc's Annual General Meeting on April 15, 2025 Nanoform Finland Plc (the “Company” or “Nanoform“) held its Annual General Meeting for 2025 on April 15, 2025 at the Company's head office in Helsinki, Finland. 42 shareholders representing 50 372 573 shares and votes were represented at the meeting (58.9% of all outstanding shares and votes). The Annual General Meeting supported all the Board of Directors' proposals. The Annual General Meeting approved

Notice to the Annual General Meeting of NANOFORM FINLAND Plc

Notice to the Annual General Meeting of NANOFORM FINLAND Plc The shareholders of Nanoform Finland Plc (the “Company”) (business ID: 2730572-8) are hereby invited to the Annual General Meeting to be held on Tuesday 15 April 2025 at 10:00 a.m. (Finnish time) at Viikinkaari 4, FI-00790 Helsinki, Finland (meeting room 105, 1. floor) (“AGM”). The reception of those who have registered for the meeting and distribution of voting tickets will start at 9:30 a.m. at the meeting venue. Shareholders can also exercise their voting rights by voting in advance. Instructions for advance voting are

Nanoform 2024 report: Deal discussions around product kernels intensify

Company Announcement Nanoform Finland Plc February 27, 2025 08:10 a.m. Finnish time / 07:10 a.m. Swedish time Nanoform 2024 report: Deal discussions around product kernels intensify After a strong second half, 2024 showed a record number of new projects signed. Revenue growth is back and is expected to continue in coming quarters and years. Other operating income (incl. product kernel milestones) is also expected to grow. Manufacturing of GMP material for pivotal studies and registration batches in Project Nanoenzalutamide has continued in a 3-shift pattern, pivotal studies

Invitation to Nanoform’s Q4 and FY 2024 Report Presentation

Press release Nanoform Finland Plc February 13, 2025 11:00 a.m. Finnish time / 10:00 a.m. Swedish time Invitation to Nanoform’s Q4 and FY 2024 Report Presentation Helsinki, Finland – Nanoform Finland Plc (“Nanoform”), the medicine performance-enhancing company, will publish its Q4 and FY 2024 report February 27, 2025, at 8.10 a.m. Finnish time / 7.10 a.m. Swedish time. The company will hold an online presentation and conference call the same day at 3.00 p.m. Finnish time / 2.00 p.m. Swedish time. Nanoform will be represented by CEO Edward Hæggström, CFO Albert Hæggström,

Nanoform Finland Plc – Manager’s Transactions – Peter Hänninen

Company release Nanoform Finland Plc December 18, 2024 17.01 Finnish time / 16.01 Swedish time Nanoform Finland Plc – Manager’s Transactions – Peter Hänninen Helsinki, Finland – Manager’s transaction related to Nanoform Finland Plc’s General Counsel and Chief Development Officer Peter Hänninen’s acceptance of stock options of Nanoform Finland Plc: Nanoform Finland Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Peter Hänninen Position: Other senior manager Issuer: Nanoform Finland

Nanoform Finland Plc – Managers’ transactions – Antonio Da Silva

Company release Nanoform Finland Plc December 18, 2024 17:01 Finnish time / 16:01 Swedish time Nanoform Finland Plc – Managers’ transactions – Antonio Da Silva Helsinki, Finland – Manager’s transaction related to Nanoform Finland Plc CBO Antonio Da Sliva’s acceptance of stock options of Nanoform Finland Plc: Nanoform Finland Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Antonio Da Silva Position: Other senior manager Issuer: Nanoform Finland Oyj LEI: 743700JJO2NU8LBS1592

Nanoform Finland Plc – Manager’s Transactions – Albert Hæggström

Company release Nanoform Finland Plc December 18, 2024 17:01 Finnish time / 16:01 Swedish time Nanoform Finland Plc – Manager’s Transactions – Albert Hæggström Helsinki, Finland – Manager’s transaction related to Nanoform Finland Plc’s Member of the Board and CFO Albert Hæggström’s acceptance of stock options of Nanoform Finland Plc: Nanoform Finland Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Albert Haeggström Position: Chief Financial Officer Issuer: Nanoform Finland Oyj

Nanoform Finland Plc – Manager’s Transactions – Edward Hæggström

Company release Nanoform Finland Plc December 18, 2024 17:01 Finnish time / 16:01 Swedish time Nanoform Finland Plc – Manager’s Transactions – Edward Hæggström Helsinki, Finland – Manager’s transaction related to Nanoform Finland Plc’s CEO Edward Hæggström’s acceptance of stock options of Nanoform Finland Plc: Nanoform Finland Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Edward Haeggström Position: Chief Executive Officer  Issuer: Nanoform Finland Oyj LEI:

The Board of Directors of Nanoform Finland Plc decided on issue of stock options under an option program open to all employees

Company release Nanoform Finland Plc December 18, 2024 17:00 Finnish time / 16:00 Swedish time The Board of Directors of Nanoform Finland Plc decided on issue of stock options under an option program open to all employees Helsinki, Finland – The Annual General Meeting of Nanoform Finland Plc (“Nanoform”) has on 16 April 2024 authorized the company’s Board of Directors to decide on the issuance of shares as well as the issuance of special rights entitling to shares referred to in Chapter 10 Section 1 of the Finnish Limited Liability Companies Act by one or several decisions.

Nanoform Finland Plc – Manager’s Transactions – Albert Hæggström

Company release Nanoform Finland Plc November 19, 2024 20.45 Finnish time / 19.45 Swedish time Nanoform Finland Plc – Manager’s Transactions – Albert Hæggström Helsinki, Finland – Manager’s transaction related to Nanoform Finland Plc’s Member of the Board and CFO Albert Hæggström’s purchase of Nanoform Finland Plc shares: Nanoform Finland Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Albert Haeggström Position: Member of the Board/Deputy member  Issuer: Nanoform Finland Oyj

Nanoform Finland Plc – Manager’s Transactions – Peter Hänninen

Company release Nanoform Finland Plc November 19, 2024 20.45 Finnish time / 19.45 Swedish time Nanoform Finland Plc – Manager’s Transactions – Peter Hänninen Helsinki, Finland – Manager’s transaction related to Nanoform Finland Plc’s General Counsel and Chief Development Officer Peter Hänninen’s purchase of Nanoform Finland Plc shares: Nanoform Finland Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Peter Hänninen Position: Other senior manager  Issuer: Nanoform FInland Oyj LEI:

Nanoform Q3 2024 report: Record number of new projects signed

Company Announcement Nanoform Finland Plc November 18, 2024 08:10 a.m. Finnish time / 07:10 a.m. Swedish time Nanoform Q3 2024 report: Record number of new projects signed A record number of new non-GMP projects signed in the quarter, helped by a significantly increased interest in our Biologics offering. Revenue growth is back and is expected to accelerate in coming quarters and years. Most GMP Quality Control analytical activities insourced after receiving Fimea license in August. Manufacturing of GMP material for pivotal studies and registration batches in Project

Invitation to Nanoform’s Q3 2024 Report Presentation

Press release Nanoform Finland Plc November 4, 2024 11:00 a.m. Finnish time / 10:00 a.m. Swedish time Invitation to Nanoform’s Q3 2024 Report Presentation Helsinki, Finland – Nanoform Finland Plc (“Nanoform”), the medicine performance-enhancing company, will publish its Q3 2024 report November 18th, 2024, at 8.10 a.m. Finnish time / 7.10 a.m. Swedish time. The company will hold an online presentation and conference call the same day at 3.00 p.m. Finnish time / 2.00 p.m. Swedish time. Nanoform will be represented by CEO Edward Hæggström, CFO Albert Hæggström and CCO

Disclosure as attachment of the Nanoform 2022 Report of the Board of Directors and Financial Statements which were previously linked to a Company Release

Company release Nanoform Finland Plc October 25, 2024 16.15 Finnish time / 15.15 Swedish time Disclosure as attachment of the Nanoform 2022 Report of the Board of Directors and Financial Statements which were previously linked to a Company Release Nanoform Finland Plc reported February 28, 2023, FY2022 results with a Company Release including Financial Statements Review for January-December 2022. In the Company Release the link to all additional documents were provided, including ‘Report of the Board of Directors and Financial Statements’, in English and Finnish. The ‘

Share subscriptions based on Nanoform Finland Plc’s stock options 2/2019

Company release Nanoform Finland Plc October 22, 2024 19.20 Finnish time / 18.20 Swedish time Share subscriptions based on Nanoform Finland Plc’s stock options 2/2019 A total of 1,000 Nanoform Finland Plc’s new shares has been subscribed for with the company's stock options 2/2019 on 14 October 2024. For subscriptions made with the stock options 2/2019 the entire subscription price of EUR 1,100.00 will be entered in the reserve for invested unrestricted equity. After the trade registration, the total number of shares is 85,531,236. The shares subscribed for under the stock

Nanoform and Celanese Expand Collaboration into Long-Acting Biologics Delivery Through Small Implants

Press release Nanoform Finland Plc September 5, 2024 08:10 a.m. Finnish time / 07:10 a.m. Swedish time Nanoform and Celanese Expand Collaboration INTO Long-Acting BIOLOGICS DELIVERY THROUGH SMALL IMPLANTS Helsinki, Finland & Dallas, US – September 5, 2024 - Nanoform Finland Plc (“Nanoform”), an innovative nanoparticle medicine enabling company, and Celanese Corporation (“Celanese”), a global specialty materials and chemical company, today announced an expansion of their collaboration to cover biologic drug delivery. The companies will combine Nanoform’s Biologics platform

Nanoform Q2 report: All business targets for 2024 on track

Company Announcement Nanoform Finland Plc August 29, 2024 08:10 a.m. Finnish time / 07:10 a.m. Swedish time Nanoform Q2 report: All business targets for 2024 on track Manufacturing of GMP material in project nanoenzalutamide continues. One or several license/commercial supply agreements are expected to be signed during 2024. Our product kernel build-out progresses well. Fimea approved our new GMP QC laboratory. A preclinical development agreement was announced with Takeda. After a burst of signings in early 3Q, including multi-API non-GMP deals with both a new and an existing

Invitation to Nanoform’s Q2 2024 Report Presentation

Press release Nanoform Finland Plc August 16, 2024 11:00 a.m. Finnish time / 10:00 a.m. Swedish time Invitation to Nanoform’s Q2 2024 Report Presentation Helsinki, Finland – Nanoform Finland Plc (“Nanoform”), the medicine performance-enhancing company, will publish its Q2 2024 report August 29[th], 2024, at 8.10 a.m. Finnish time / 7.10 a.m. Swedish time. The company will hold an online presentation and conference call the same day at 3.00 p.m. Finnish time / 2.00 p.m. Swedish time. Nanoform will be represented by CEO Edward Hæggström, CFO Albert Hæggström and CCO

NANOFORM COLLABORATES WITH TAKEDA ON THEIR PLASMA-DERIVED THERAPY DEVELOPMENT

Press release Nanoform Finland Plc August 15, 2024 08:10 a.m. Finnish time / 07:10 a.m. Swedish time Nanoform COLLABORATES WITH TAKEDA on THEIR PLASMA-DERIVED Therapy Development Helsinki, Finland – August 15, 2024 - Nanoform Finland Plc (“Nanoform”), the medicine performance-enhancing company, today announced that it is to enter into a pre-clinical development agreement with the Plasma-derived Therapies Business Unit of Takeda Pharmaceuticals, Inc., the R&D-driven biopharmaceutical company headquartered in Japan, to develop innovative plasma-derived therapy formulations for

Nanoform Finland Plc – Manager’s Transactions – Miguel Calado

Company release Nanoform Finland Plc June 14, 2024 17.01 Finnish time / 16.01 Swedish time Nanoform Finland Plc – Manager’s Transactions – Miguel Calado Helsinki, Finland – Manager’s transaction related to Nanoform Finland Plc’s Chairman of the Board Miguel Calado’s purchase of Nanoform Finland Plc shares: Nanoform Finland Oyj - Managers' Transactions Person subject to the notification requirement Name: Miguel Calado Position: Member of the Board/Deputy member Issuer: Nanoform Finland Oyj LEI: 743700JJO2NU8LBS1592 Notification type: INITIAL NOTIFICATION

Nanoform Finland Plc – Manager’s Transactions – Albert Hæggström

Company release Nanoform Finland Plc June 14, 2024 17.01 Finnish time / 16.01 Swedish time Nanoform Finland Plc – Manager’s Transactions – Albert Hæggström Helsinki, Finland – Manager’s transaction related to Nanoform Finland Plc’s Member of the Board Albert Hæggström’s purchase of Nanoform Finland Plc shares: Nanoform Finland Oyj - Managers' Transactions Person subject to the notification requirement Name: Albert Hæggström Position: Member of the Board/Deputy member  Issuer: Nanoform Finland Oyj LEI: 743700JJO2NU8LBS1592 Notification type: INITIAL

Nanoform Finland Plc – Manager’s Transactions – Mads Laustsen

Company release Nanoform Finland Plc June 14, 2024 17.01 Finnish time / 16.01 Swedish time Nanoform Finland Plc – Manager’s Transactions – Mads Laustsen Helsinki, Finland – Manager’s transaction related to Nanoform Finland Plc’s Member of the Board Mads Laustsen’s purchase of Nanoform Finland Plc shares: Nanoform Finland Oyj - Managers' Transactions Person subject to the notification requirement Name: Mads Laustsen Position: Member of the Board/Deputy member  Issuer: Nanoform Finland Oyj LEI: 743700JJO2NU8LBS1592 Notification type: INITIAL NOTIFICATION

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe

Media